lonafarnib has been researched along with carboplatin in 2 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (carboplatin) | Trials (carboplatin) | Recent Studies (post-2010) (carboplatin) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 12,895 | 4,001 | 5,244 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumann, K; Belau, A; Burges, A; Canzler, U; du Bois, A; Gropp-Meier, M; Huober, J; Kreienberg, R; Meier, W; Rau, J; Richter, B; Schmalfeldt, B; Schröder, W; Sehouli, J; Stähle, A; Wimberger, P; Wollschlaeger, K | 1 |
| Aminossadati, B; Bachmann, HS; Burges, A; du Bois, A; Hillemanns, P; Huober, J; Kimmig, R; Kuhlmann, JD; Meier, W; Schmalfeldt, B; Sehouli, J; Siffert, W; Wimberger, P; Wollschlaeger, K | 1 |
2 trial(s) available for lonafarnib and carboplatin
| Article | Year |
|---|---|
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Piperidines; Prospective Studies; Pyridines; Survival Analysis; Young Adult | 2012 |
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Carboplatin; Farnesyltranstransferase; Female; Genetic Markers; Genotype; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Piperidines; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Subunits; Pyridines; Treatment Outcome; Young Adult | 2015 |